Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Endometrial Neoplasms 1

Interventions

antineoplaston AS 2-1 4antineoplaston A10 4Cyclophosphamide 4Cisplatin 4Temozolomide 3Radiotherapy 3dactolisib 2Vincristine 2Filgrastim 2Everolimus 2Etoposide 2Bevacizumab 2spartalizumab 1sargramostim 1pasireotide 1ganitumab 1gallium Ga 68 dotatate 1fosbretabulin 1cixutumumab 1belzutifan 1aldesleukin 1Topotecan 1Thiotepa 1TH 302 1Sunitinib 1Standard of Care 1Pregabalin 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroectodermal Tumors, Primitive × PM 00104 × Clear all
NCT01222767 2021-10-29

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

PharmaMar

Phase 2 Completed
17 enrolled 20 charts
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡